Free Trial

ABVC BioPharma (ABVC) Competitors

ABVC BioPharma logo
$2.94 -0.02 (-0.51%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ABVC vs. ENGN, AVTE, IPHA, MDWD, GNFT, DMAC, EPRX, CTMX, CRBU, and ELDN

Should you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include enGene (ENGN), Aerovate Therapeutics (AVTE), Innate Pharma (IPHA), MediWound (MDWD), GENFIT (GNFT), DiaMedica Therapeutics (DMAC), Eupraxia Pharmaceuticals (EPRX), CytomX Therapeutics (CTMX), Caribou Biosciences (CRBU), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry.

ABVC BioPharma vs. Its Competitors

ABVC BioPharma (NASDAQ:ABVC) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, ABVC BioPharma and ABVC BioPharma both had 4 articles in the media. ABVC BioPharma's average media sentiment score of 0.58 beat enGene's score of 0.40 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ABVC BioPharma
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
enGene
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

enGene has a consensus target price of $23.29, suggesting a potential upside of 529.17%. Given enGene's stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than ABVC BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABVC BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
enGene
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

enGene has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. ABVC BioPharma's return on equity of -29.62% beat enGene's return on equity.

Company Net Margins Return on Equity Return on Assets
ABVC BioPharma-963.46% -29.62% -14.08%
enGene N/A -32.60%-28.26%

ABVC BioPharma has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.41, suggesting that its stock price is 141% less volatile than the S&P 500.

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 17.1% of ABVC BioPharma shares are held by insiders. Comparatively, 10.4% of enGene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ABVC BioPharma has higher revenue and earnings than enGene. ABVC BioPharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ABVC BioPharma$510K97.72-$4.90M-$0.13-22.58
enGeneN/AN/A-$55.14M-$1.65-2.24

Summary

ABVC BioPharma beats enGene on 8 of the 15 factors compared between the two stocks.

Get ABVC BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABVC vs. The Competition

MetricABVC BioPharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$49.75M$3.03B$5.50B$9.81B
Dividend YieldN/A2.28%4.59%4.13%
P/E Ratio-22.5417.3829.9425.16
Price / Sales97.72349.44445.68102.78
Price / CashN/A40.7324.8128.01
Price / Book48.928.988.685.82
Net Income-$4.90M-$54.75M$3.26B$265.22M
7 Day Performance-2.17%-0.94%0.61%0.75%
1 Month Performance-26.07%7.33%3.33%1.97%
1 Year Performance327.34%23.30%45.75%27.33%

ABVC BioPharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABVC
ABVC BioPharma
0.9922 of 5 stars
$2.94
-0.5%
N/A+328.2%$49.75M$510K-22.5430Upcoming Earnings
ENGN
enGene
3.3277 of 5 stars
$3.94
+3.1%
$23.29
+491.0%
-44.2%$201.33MN/A-2.3931
AVTE
Aerovate Therapeutics
N/A$6.89
-4.2%
N/A-87.3%$199.71MN/A-2.3020News Coverage
High Trading Volume
IPHA
Innate Pharma
2.559 of 5 stars
$2.14
+1.4%
$11.00
+414.0%
-8.8%$197.27M$21.77M0.00220
MDWD
MediWound
2.0289 of 5 stars
$17.96
-2.2%
$32.25
+79.6%
+3.7%$194.11M$19.21M-8.5980Upcoming Earnings
GNFT
GENFIT
1.2929 of 5 stars
$3.88
+2.3%
$13.00
+235.4%
-5.1%$193.80M$76.77M0.00120
DMAC
DiaMedica Therapeutics
1.771 of 5 stars
$4.49
+3.0%
$10.75
+139.4%
+29.0%$192.53MN/A-7.0220News Coverage
High Trading Volume
EPRX
Eupraxia Pharmaceuticals
2.7791 of 5 stars
$5.35
-0.5%
$11.00
+105.5%
+98.5%$192.53MN/A-7.0429
CTMX
CytomX Therapeutics
4.0065 of 5 stars
$2.37
-0.8%
$5.75
+142.6%
+92.5%$191.07M$138.10M4.94170Analyst Revision
Gap Down
CRBU
Caribou Biosciences
2.4841 of 5 stars
$2.04
-2.9%
$8.50
+316.7%
-11.9%$189.72M$9.99M-1.26100
ELDN
Eledon Pharmaceuticals
1.7024 of 5 stars
$3.13
-3.7%
$10.00
+219.5%
+3.4%$187.42MN/A-1.4910News Coverage
Upcoming Earnings
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ABVC) was last updated on 8/12/2025 by MarketBeat.com Staff
From Our Partners